Funding   |   Policy Updates

Regenerative Medicine Gets Boost in Fiscal Year 2018 Omnibus Appropriations Package

ASGCT Staff - March 26, 2018

After five stopgap continuing resolutions since the fiscal year began October 1, and two brief partial government shutdowns, President Trump on Friday signed into law the Omnibus Appropriations Package which included an 8.8 percent year-over-year budget increase for the NIH.

After five stopgap continuing resolutions since the fiscal year began October 1, and two brief partial government shutdowns, President Trump on Friday signed into law the Omnibus Appropriations Package. The legislation provides $37 billion for the National Institutes of Health (NIH), representing an increase of $3 billion, or 8.8 percent, above fiscal year 2017, including $496 million for initiatives authorized by the 21st Century Cures Act.

Most notable for the gene and cell therapy fields, NIH funding includes $10 million in funding for regenerative medicine research, a significant $8 million increase from 2017 funding. The 2018 NIH appropriations also provide an increase of $134 million above fiscal year 2017 for the Food and Drug Administration.

The final legislation did not include a provision contained in the original House appropriations bill (HR 3358) that would have placed restrictions on federal funding for research using human fetal tissue. ASGCT joined 62 other organizations last summer in signing on to a letter opposing such restrictions.

Related Articles

ASGCT News

Gene, Cell, & RNA Therapy Landscape: Q1 2021

David M. Barrett, J.D., M.S. - April 15, 2021
Policy Updates

FDA, NIH Issue Guidance on Conducting Clinical Trials During a Pandemic

ASGCT Staff - April 06, 2020
Policy Updates

ASGCT Applauds FDA's Gene Therapy Guidance Documents

Adora Ndu, PharmD, J.D. - February 03, 2020
Policy Updates

ASGCT Invited to Join USP as a Voting Member

ASGCT Staff - January 08, 2020